Close

Jump to:

  • Navigation
  • Content
  • Footer
Flexyfoot hero image

Flexyfoot

Follow

For anyone who needs a walking stick, walking cane or crutches to get around.

150%
 - 
Funded 25 Jul 2016
£100,003 target
£150,001 from 125 investors
More
Less

Business overview

Location Woking, United Kingdom
Social media
Website www.flexyfoot.com
Sectors Home & Personal Mixed Digital/Non-Digital Mixed B2B/B2C
Company number 6721191
Incorporation date 13 Oct 2008
More
Less

Investment summary

Type Equity
Valuation (pre-money) £1.2M
Equity offered 11.14%
Tax relief

EIS

  • Idea
  • Market
  • Team
  • Updates
  • Investors 125
  • Discussion
  • Documents

Idea

Introduction

Flexyfoot puts a suspension system on the bottom of walking aids such as crutches and walking sticks. This helps to prevent injuries that are common to people who have to use these aids and also provides greater comfort.

Flexyfoot’s patented design is based on a moulded bellows that automatically adjusts to the terrain so that the whole of the tread is in contact with the ground with each step. This dramatically improves grip. At the same time the bellows is absorbing the shock and impact that the user applies; this would otherwise be absorbed by their body, which is uncomfortable and can result in long-term injuries. It has been endorsed by senior people within the industry and by medical professionals.

Intended impact

There are a number of problems associated with traditional walking aids:

1. Anecdotal evidence suggests that many people resist using walking aids such as a stick, due to their perception that the walking stick makes them look and feel older.

2. These “non-users” are much more vulnerable to slips and falls, which can result in broken hips and bones. The impact on both the person and their health provider can be very significant.

3. Traditional walking aids use a simple rubber ferule to supply grip. This primitive technology provides limited grip, particularly on smooth surfaces during the vulnerable first contact, and does not provide any shock absorbency. This means users of traditional walking aids remain vulnerable to slips and falls.

4. People that are longer-term users of traditional walking aids often develop musculoskeletal injuries such as repetitive strain injuries to hands, wrists, arms and shoulders, as well as long-term impact injuries to joints, tendons and muscles. These problems are well documented in medical research papers, from feedback from medical professions such as orthopaedic surgeons and physiotherapists, and from direct patient feedback.

We believe that Flexyfoot solves all of the above problems, “putting the spring back in to your step”. Using our proven and award-winning design and engineering skills, we have designed a unique range of walking aids that project a young and dynamic image, coupled with all the functional benefits of the Flexyfoot technology.

Substantial accomplishments to date

◆ 2015 sales of £153k, +22% on prior year*, aiming for significant growth in 2016.

◆ Substantial investment in marketing: press coverage, point of sale materials, packaging options, videos and TV ads.

◆ Sales to 37 countries without any investment in international marketing.

◆ April 2016: A large Chinese medical distributor has committed to significant & increasing minimum orders during each of the next 5 years.

◆ We are working with one of Germany’s leading manufacturer of crutches and walking sticks on plans to co-invest in their marketing activity for Flexyfoot in Germany.

◆ Expanded from the Flexyfoot ferrule to a complete range of walking sticks and crutches.

◆ Have built our own database of 4,800+ customers and prospects.

◆ Patents granted in USA, Japan, China, South Africa and Australia, and pending patent in the EU and India.

◆ Proven, reliable, cost-effective production process established. Flexyfoot is CE-marked, complies with BS EN standards.

*source: Unaudited management accounts

Monetisation strategy

1. We have proven our ability to monetise Flexyfoot: In 2015 we achieve Sales of £153k, an increase of 22% over the prior year, at a gross margin of 44%*.

2. Two thirds of our 2015 sales were in the UK (£100k), where we sell via a mixture of direct and trade channels. Our marketing investment focused on generating end-user demand. As this demand has grown, trade channels (including Boots) have shown growing interest in stocking our products.

3. Beyond the UK, we have been successful in selling small volumes to customers who actively research mobility aids. We want to repeat our success in the UK by working with local distributors in our chosen markets, co-investing in marketing activities that will be tailored to each country, but will build upon the experience and investment that we have already gained in the UK.

4. Recurring revenues: Flexyfoot lasts longer than the conventional ferrule due to way it wears, but there is still a need to replace the tread. Replacement is a simple procedure, costing 50% of the cost of a complete Flexyfoot. Historically replacement sales have accounted for 18% of our sales. This demonstrates that people live and stay with Flexyfoot.

5. Expanding product range: We started with the core Flexyfoot ferrule and have grown our product range to include walking sticks, crutches, and the Ice Foot, which includes a stainless array of teeth that dig into snow and ice. Sales of these has proven to be very successful and are a useful add-on purchase.

Our aim is to continue to build a consumer brand in a sector that to our knowledge has very few genuine brands. Our brand stands for Safety, Security, Comfort and Style. Under this umbrella we will develop a product range to improve peoples’ lives and to put a smile on their faces. We see our model is what James Dyson did to the vacuum cleaner market: transforming the price point and profile through design, usability and marketing.

*source: Unaudited management accounts

Use of proceeds

We intend to co-invest in a country-specific marketing plan agreed with selected overseas distributors. Co-investment would foster much greater commitment to achieving sales targets.

We are already in discussions with two international distributors:

1. GERMANY: Our distributor, Ossenberg, has agreed to match our commitment of up to €30k to marketing spend in the coming year. The majority of this budget will fund an identified member of their team. We are also preparing to launch Flexyfoot in Germany at the OTWorld Trade Show in May.

2. JAPAN: We are in discussions with Abilities, a significant organisation in the Japanese Mobility-Aids market. Flexyfoot will be launched at a major Japanese trade show in October and we are encouraging Abilities to adopt a similar, co-investment approach to marketing to Germany.

We want to execute our plans in these markets as soon as possible and then move on to other selected markets in subsequent years.

Market

Target market

Throughout the world people are living longer and want to lead more active lives and so our market is growing year on year.

Our business plan is based on the following assumptions:

1. Our plan assumes that the bulk of our revenue is earned in 6 markets: UK, Germany, China, Japan, South Korea and the USA. We already have a significant presence in the UK and active distributors in Germany, China and South Korea.

2. The combined population of these 6 countries is 2,024 million.

3. We estimate that 4% of a country’s population typically uses some sort of walking aid. As an example – in the UK, this would mean that 2.6m people use a walking aid [4% of 65 million]. This is proven to be a conservative assumption by a survey conducted by the UK’s Office for National Statistics in 2001 that stated this figure at 4.1m.

4. We then assume an average of 1.5 Flexyfeet per head – i.e. half the people with mobility problems use a stick (1 Flexyfoot), the other half use crutches (2 Flexyfeet).

5. Based on our current pricing, this would suggest the total value of the addressable market in these 6 countries is £870m.

Characteristics of target market

It is our opinion that the best route to market is to communicate to the consumer for self-purchase. They either retro-fit Flexyfoot to their existing walking -aid, or buy a complete Flexyfoot aid.

Our customers purchase directly from us, or from one of various trade outlets that stock Flexyfoot (typically these are pharmacy chains or specialist mobility aid retailers).

Healthcare providers, such as the UK's National Health Service, are a significant opportunity. However, we have found that these organisations are not set up to review and approve new mobility products, and tend to focus on minimising their purchase costs, as opposed to assessing the long-term benefits of reduced patient injuries. This does not preclude sales to the healthcare system, and we anticipate that over time the benefits are likely to be accepted and then we become standard fit.

Marketing strategy

We are building Flexyfoot as the go-to consumer brand for people who want to be more mobile without the stigma associated with many mobility aid products.

To date, our marketing has been UK-focused. Our own user survey revealed that the most responsive customer is a woman aged 50+ who buys for herself or for a family member. We have used appropriate PR, SEO, social media, and events to successfully sell to this demographic. We also work with charities that support sufferers of disabling conditions. Trade shows such as Naidex (UK) and Rehacare (Germany) have been an important channel for recruiting distributors and influential customers.

Our next goal is to develop our international presence. We plan to work much more closely with selected international distributors, using marketing co-investment to trigger active engagement. In Germany, our distributor has agreed to jointly fund a Flexyfoot Brand Manager. This will run in parallel with their cross marketing.

Japan has an ageing and wealthy population of 120M. Our distributor sells rehabilitation equipment and mobility products, as well as operating care homes. The founder has used crutches since youth and is a keen Flexyfoot supporter. We are co-exhibiting at Japan’s major rehab show in October and plan to dedicate a person to drive the sales to retail, healthcare and direct to consumer.

South Korea is proving to be a good market and we have a very active distributor who is moving into retail using our collateral materials.

And in China, we have just signed up one of the largest medical distributor. They have committed to significant & increasing minimum orders during each of the next 5 years. We believe they see Flexyfoot as a high value Western brand.

Competition strategy

In terms of retro-fit ferrules or tips, to our knowledge there is very little or no direct competition to Flexyfoot and certainly not at our price point. We have the opportunity to adjust our sales price as our current margins are high and the technology lends itself to automation and high volume if and when we choose to fully automate production. We can therefore reduce our unit manufacturing costs further. The core technology, the bellows, is an extremely cost effective part and uses the same manufacturing machinery as a drinks bottle (but with our own tooling).

As far as we know the vast majority of sticks and crutches in the world are made in either China or India and there is very little differentiation between them. Some are decorated with fancy patterns but still use similar handles, metalwork and tips. There are of course some quality differences which translate into end user prices. As far as we know some countries such as China and Japan do not classify walking sticks as medical devices and therefore do not need to meet the same International Standards that Flexyfoot.

Typically sticks retail from around £10 to £30. When thinking about the benefits a stick can provide, or the health issues and cost arising from not using a stick, these prices are very modest indeed.

We have positioned our sticks at the top end as we are not seeking to sell very high volumes with low margins as there would be insufficient margin to invest in marketing to establish a brand that is sustainable long-term.

We believe that the trick to communicate the features and benefits rather than price. Our sticks sell for £39.95 in the UK.

Open an account to get access to the team members of Flexyfoot

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for Flexyfoot has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 20 June 2016 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £1,196,000

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Seedrs.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel